Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients

Abstract

This invention relates to a method for managing the risk of an adverse interaction between teriflunomide and a substrate of breast cancer resistance protein (BCRP) and/or organic anion transporting polypeptide B1 and B3 (OATP1B1/B3).

We claim: 
     
         1 . A method of providing teriflunomide wherein the teriflunomide is provided along with information indicating that it is useful for treating patients with relapsing forms of multiple sclerosis, and in cases said patients also receive treatment of rosuvastatin wherein rosuvastatin is co-administered with teriflunomide, reducing the dose of rosuvastatin to not exceeding 10 mg once daily is recommended. 
     
     
         2 . A method of promoting the use of teriflunomide comprising conveying to a recipient at least one message comprising teriflunomide is useful for treating relapsing forms of multiple sclerosis, and in cases said patients also receive treatment of rosuvastatin wherein rosuvastatin is co-administered with teriflunomide, reducing the dose of rosuvastatin to not exceeding 10 mg once daily is recommended. 
     
     
         3 . A method for administering a combination of teriflunomide and rosuvastatin to a patient having multiple sclerosis, comprising administering to the patient about 7 or 14 mg of teriflunomide daily, and co-administering to the patient rosuvastatin at a dose that does not exceed 10 mg once daily. 
     
     
         4 . The method according to  claim 3 , wherein the patient has relapsing forms of multiple sclerosis. 
     
     
         5 . The method according to  claim 3 , wherein rosuvastatin is co-administered with teriflunomide at the same time. 
     
     
         6 . The method according to  claim 4 , wherein rosuvastatin is co-administered with teriflunomide at the same time.